Chagasin is a small (110-residue), heat-stable, secreted-pathway protein of Trypanosoma cruzi and the signature member of the I42 family of natural cysteine peptidase inhibitors. It adopts an immunoglobulin-like fold unrelated to the cystatins, and presents three loops (BC/L2, DE/L4 and FG/L6) on one face as a tripartite wedge that occludes the substrate-binding cleft of papain-family (clan CA, family C1) cysteine peptidases; the central BC loop inserts into the catalytic centre and contacts the catalytic cysteine and histidine. Binding is 1:1, reversible and picomolar, and it is broad across the C1 family: chagasin inactivates papain, human cathepsins L and B, the Plasmodium protease falcipain-2, and, above all, cruzipain, the parasite's own major lysosomal cysteine peptidase. Inside the parasite, chagasin and cruzipain traffic through overlapping compartments, and inhibitory complexes between them are recovered from living cells; raising chagasin levels genetically collapses parasite peptidase activity, which in turn slows metacyclogenesis and lowers infectivity for mammalian cells. Its demonstrated biological role is therefore the endogenous rheostat of the parasite's own proteolysis. Immunogold electron microscopy places chagasin in the flagellar (ciliary) pocket and cytoplasmic vesicles of trypomastigotes, on the cell surface of amastigotes, and, together with cruzipain, in the Golgi complex and in reservosomes. Its tight inhibition of host cathepsins L and B is well characterised structurally but has so far been shown only with purified enzymes.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
| GO:0004869 cysteine-type endopeptidase inhibitor activity | IDA PMID:11719560 Identification, characterization and localization of chagasi... | ACCEPT | Summary: This is the defining activity of the protein and of its whole inhibitor family. The discovery paper isolated a heat-stable cruzipain-binding protein from epimastigote lysates and characterised it kinetically as a tight-binding, reversible inhibitor of papain-like cysteine proteases; later kinetics put the dissociation constants in the picomolar range against papain, cruzipain, human cathepsin L and human cathepsin B, and five crystal or NMR structures show the three-loop wedge blocking the catalytic cleft. Core function. Reason: CACAO row (ASSIGNED BY CACAO, 2013-02-10). What the cited paper shows for this gene: enzyme-inhibition kinetics on the purified 12 kDa protein isolated from epimastigotes, reported in the abstract as characterisation as a "tight-binding and reversible inhibitor of papain-like cysteine proteases". The CACAO term matches that assay exactly: GO:0004869 is defined as binding to and reducing the activity of a cysteine-type endopeptidase, which is what was measured, and IDA fits a direct kinetic assay on the purified protein. The term is also correctly target-agnostic, which matters for this gene, because chagasin inhibits both the parasite's own cruzipain and host cathepsins L and B, and a molecular-function term should not be forced to choose. It is neither too downstream (no phenotype is being read as an activity here) nor the wrong granularity, since the only child of GO:0004869 is the apoptosis-context term GO:0010859, which does not apply. UniProt curates the same function from the same paper with ECO:0000269. The full text is not in the cache, but the abstract states the assayed claim outright, so no deference problem arises. Supporting Evidence: PMID:11719560 This protein was subsequently characterized as a tight-binding and reversible inhibitor of papain-like cysteine proteases. PMID:18201565 It is a single 110-residue polypeptide chain with no sequence similarity to other known groups of CP inhibitors and potently inactivates papain-like enzymes through the formation of 1:1 tight–binding complexes. PMID:19143838 inactivation of papain by chagasin is very fast (k(on) = 1.5 x 10(6) M(-1) x s(-1)), and results in the formation of a very tight, reversible complex (K(i) = 36 pM) file:genes/TRYCR/cha/cha-uniprot.txt Inhibits cysteine protease cruzipain |
| GO:0005515 protein binding | IPI PMID:17502099 The structure of chagasin in complex with a cysteine proteas... | MODIFY | Summary: An IntAct import recording the chagasin-falcipain-2 complex solved in PMID:17502099. The interaction is real and structurally characterised, but the bare term carries no functional information, and the same paper supports the informative replacement directly, since UniProt cites it with ECO:0000269 for chagasin's cysteine protease inhibitor function. Reason: Not a CACAO row (ASSIGNED BY IntAct). Per the generic-protein-binding policy, GO:0005515 is replaced by the informative molecular function the cited paper actually supports rather than removed outright. PMID:17502099 reports the 2.2 A crystal structure of chagasin in complex with a cysteine protease and is cited by UniProt as ECO:0000269 evidence for the inhibitor function, so GO:0004869 is the evidence-backed replacement and is already asserted elsewhere in this review. Nothing here asserts that the reported interaction is false. Worth recording for interpretation, the partner UniProtKB:Q9NBD4 is falcipain-2 of Plasmodium falciparum, used as a crystallographic surrogate for cruzipain. T. cruzi and P. falciparum share no host cell, so this row is not evidence of a physiological partner and must not be read as support for a host-directed or co-infection role. Proposed replacements: cysteine-type endopeptidase inhibitor activity Supporting Evidence: PMID:17502099 We report the 2.2 A crystal structure of the signature member of the I42 family, chagasin, in complex with a cysteine protease. PMID:17502099 Interactions of chagasin with a target protease are reminiscent of the cystatin family inhibitors. |
| GO:0009986 cell surface | IDA PMID:11719560 Identification, characterization and localization of chagasi... | ACCEPT | Summary: Immunogold electron microscopy localised chagasin to the cell surface of amastigotes, and binding assays on living, unpermeabilised parasites with FITC-chagasin and FITC-cruzipain independently placed both the inhibitor and its target protease at the amastigote surface. Two different assays, one of them on intact live cells, support the same location. Reason: CACAO row (ASSIGNED BY CACAO, 2013-02-10). What the cited paper shows for this gene, gold-labelled antibody EM on amastigotes plus FITC-probe binding to living parasites. The CACAO term matches the assay, since GO:0009986 is defined as the external part of the cell wall and/or plasma membrane, which is where a surface-accessible FITC probe binds. It is not too downstream, and not the wrong granularity, because the EM and probe data establish surface accessibility but do not resolve whether chagasin is peripherally associated with the outer leaflet or in some other surface sub-compartment, so no child of GO:0009986 is warranted. This is explicitly not the project's single-assay-localization pattern, because two independent assays agree. UniProt curates Cell surface for this entry from the same paper with ECO:0000269 from PubMed:11719560. The surface pool is also the biologically interesting one, since membrane-associated peptidase activity is what the infectivity phenotype in PMID:15713748 traces to. Supporting Evidence: PMID:11719560 Gold-labeled antibodies localized chagasin to the flagellar pocket and cytoplasmic vesicles of trypomastigotes and to the cell surface of amastigotes. PMID:11719560 Binding assays performed by probing living parasites with fluorescein (FITC)-cruzipain or FITC-chagasin revealed the presence of both inhibitor and protease at the cell surface of amastigotes. file:genes/TRYCR/cha/cha-uniprot.txt Cytoplasmic vesicle {ECO:0000269|PubMed:11719560}. Cell surface |
| GO:0009986 cell surface | IEA GO_REF:0000044 | ACCEPT | Summary: An electronic restatement of UniProt's curated SUBCELLULAR LOCATION "Cell surface" via the SubCell-to-GO mapping. The underlying UniProt statement is not itself electronic, as it carries ECO:0000269 from PubMed:11719560, the same immunogold EM and live-cell FITC-probe data that support the IDA row above. Reason: The mapping of SL-0310 to GO:0009986 is exact and the curated location it propagates is experimentally grounded, so this row reinforces the IDA row rather than duplicating a weak inference. Keeping it is consistent with the ACCEPT on the IDA row for the same term, as required. Supporting Evidence: file:genes/TRYCR/cha/cha-uniprot.txt Cytoplasmic vesicle {ECO:0000269|PubMed:11719560}. Cell surface PMID:11719560 Binding assays performed by probing living parasites with fluorescein (FITC)-cruzipain or FITC-chagasin revealed the presence of both inhibitor and protease at the cell surface of amastigotes. |
| GO:0020016 ciliary pocket | IDA PMID:11719560 Identification, characterization and localization of chagasi... | ACCEPT | Summary: Immunogold EM localised chagasin to the flagellar pocket of trypomastigotes. "Flagellar pocket" is an exact synonym of GO:0020016 ciliary pocket (verified in QuickGO), so this is a direct term match, not an interpretation. The flagellar pocket is the sole site of endocytosis and exocytosis in trypanosomatids, which is exactly where an inhibitor would meet cruzipain in transit. Reason: CACAO row (ASSIGNED BY CACAO, 2013-02-10). What the cited paper shows for this gene, gold-labelled antibody EM on trypomastigotes placing chagasin in the flagellar pocket. The CACAO term is the correct one and at the correct granularity, since GO:0020016 is defined as the invagination of the plasma membrane from which a cilium (also called flagellum) protrudes, and the term's own exact synonym is "flagellar pocket", so the student matched the paper's wording to the ontology correctly. The row is not too downstream and not unsupported. Its children (ciliary pocket membrane and the collar terms) are not warranted, because the EM resolved the compartment but not a membrane-versus-lumen assignment. UniProt independently curates Flagellar pocket from the same paper with ECO:0000269 from PubMed:11719560. Supporting Evidence: PMID:11719560 Gold-labeled antibodies localized chagasin to the flagellar pocket and cytoplasmic vesicles of trypomastigotes and to the cell surface of amastigotes. file:genes/TRYCR/cha/cha-uniprot.txt SUBCELLULAR LOCATION: Flagellar pocket {ECO:0000269|PubMed:11719560}. |
| GO:0020016 ciliary pocket | IEA GO_REF:0000044 | ACCEPT | Summary: Electronic restatement of UniProt's curated "Flagellar pocket" location through the SubCell-to-GO mapping. SL-0116 maps to GO:0020016, whose exact synonym is flagellar pocket, so the mapping is faithful, and the curated statement it propagates carries ECO:0000269 from PubMed:11719560. Reason: The electronic mapping is exact and the UniProt location behind it is experimental, not predicted, so this row reinforces the IDA row for the same term and is kept with the same action. Supporting Evidence: file:genes/TRYCR/cha/cha-uniprot.txt SUBCELLULAR LOCATION: Flagellar pocket {ECO:0000269|PubMed:11719560}. PMID:11719560 Gold-labeled antibodies localized chagasin to the flagellar pocket and cytoplasmic vesicles of trypomastigotes and to the cell surface of amastigotes. |
| GO:0031410 cytoplasmic vesicle | IDA PMID:11719560 Identification, characterization and localization of chagasi... | ACCEPT | Summary: Immunogold EM localised chagasin to cytoplasmic vesicles of trypomastigotes. The follow-up study four years later, with better ultrastructural resolution, still describes the free (uncomplexed) chagasin pool only as "small intracellular vesicles", so the parent-level term remains the most specific honest statement for this pool, even though the complexed pool was resolved to Golgi and reservosomes. Reason: CACAO row (ASSIGNED BY CACAO, 2013-02-10). What the cited paper shows for this gene, gold-labelled antibody EM on trypomastigotes showing chagasin in cytoplasmic vesicles. The CACAO term matches the reported observation. This row initially looks like the project's parent-level-restatement or wrong-granularity pattern, but it is not, because the 2001 EM did not identify the vesicle class, and PMID:15713748, which did resolve two compartments for the chagasin-cruzipain complex (Golgi complex and reservosomes), still leaves the free-chagasin vesicles unidentified. GO:0031410 is therefore correctly general rather than over-general, and under the correct-but-general rule this is the case where the general term is already as precise as the evidence allows, so it is kept. The resolved compartments are added as separate NEW rows below rather than substituted here, since they describe a different pool. UniProt curates Cytoplasmic vesicle from the same paper with ECO:0000269 from PubMed:11719560 and carries the matching keyword. Supporting Evidence: PMID:11719560 Gold-labeled antibodies localized chagasin to the flagellar pocket and cytoplasmic vesicles of trypomastigotes and to the cell surface of amastigotes. PMID:15713748 Ultrastructural studies showed that chagasin and cruzipain both localize to the Golgi complex and reservosomes (lysosome-like organelles), whereas free chagasin was found in small intracellular vesicles file:genes/TRYCR/cha/cha-uniprot.txt Cytoplasmic vesicle {ECO:0000269|PubMed:11719560}. Cell surface |
| GO:0031410 cytoplasmic vesicle | IEA GO_REF:0000044 | ACCEPT | Summary: Electronic restatement of UniProt's curated "Cytoplasmic vesicle" location through the SubCell-to-GO mapping (SL-0088 to GO:0031410). The curated statement it propagates carries ECO:0000269 from PubMed:11719560. Reason: Faithful mapping of an experimentally grounded curated location, consistent with the ACCEPT on the IDA row for the same term. Supporting Evidence: file:genes/TRYCR/cha/cha-uniprot.txt Cytoplasmic vesicle {ECO:0000269|PubMed:11719560}. Cell surface PMID:11719560 Gold-labeled antibodies localized chagasin to the flagellar pocket and cytoplasmic vesicles of trypomastigotes and to the cell surface of amastigotes. |
| GO:0010951 negative regulation of endopeptidase activity | IMP PMID:15713748 Chagasin, the endogenous cysteine-protease inhibitor of Tryp... | NEW | Summary: GOA carries no biological-process annotation for chagasin at all, yet the one process claim the literature does establish is squarely about this gene product, namely that chagasin sets the level of active cysteine peptidase inside the living parasite. T. cruzi lines transfected to overexpress chagasin show a fourfold rise in cysteine peptidase inhibitory activity, a drastic fall in soluble cruzipain activity (about 80% loss of active peptidase) and increased resistance to a synthetic peptidase inhibitor, and chagasin-cruzipain complexes are recovered directly from epimastigotes. Reason: Participation test, chagasin itself performs the inhibitory step. It binds the peptidase 1:1 through its three-loop wedge and occludes the catalytic centre, so it is the entity that does the work of the regulation, not merely something required for or consumed by it. Comparator check, GO:0010951 is used in exactly this way for protein protease inhibitors, by IDA, on TIMP1 (PMID:3903517), SERPINB1 (PMID:30692621), SERPINB8 (PMID:8530382) and SERPINB13 (PMID:12504904), so this is the established convention for an inhibitor rather than a gap being invented. The term is also the most specific one available, because GO:2000117 negative regulation of cysteine-type endopeptidase activity is obsolete (verified in QuickGO), so no descendant is being skipped. The row is deliberately restricted to the parasite's own peptidases and makes no interspecies claim. No symbiont-mediated or host-directed process term is proposed, because inhibition of host cathepsins L and B has only ever been shown with purified enzymes and never inside an infected host cell. Also deliberately not proposed are metacyclogenesis or host-cell invasion process terms, since the authors state the modulation of those is indirect, mediated by the peptidase, and chagasin performs no step of either. Supporting Evidence: PMID:15713748 These phenotypic changes were accompanied by a drastic reduction of soluble cruzipain activity and by upregulated secretion of cruzipain-chagasin molecular complexes. PMID:15713748 we obtained direct evidence that chagasin-cruzipain complexes are indeed formed in epimastigotes PMID:18201565 T. cruzi lines that overexpress chagasin have an 80% decrease in active CPs, are less capable to differentiate and are less infective to mammalian cells in vitro |
| GO:0106123 reservosome | IDA PMID:15713748 Chagasin, the endogenous cysteine-protease inhibitor of Tryp... | NEW | Summary: Ultrastructural immunolocalisation placed chagasin, together with cruzipain, in reservosomes, the lysosome-like endocytic storage organelles of epimastigote-stage T. cruzi. GOA has no row for this compartment, which is the one place where the inhibitor and its physiological target were shown to be co-resident. Reason: GO:0106123 was created specifically for this organelle, defined as present only in members of the Schizotrypanum subgenus of the Trypanosoma genus and as the site of storage of endocytosed macromolecules and lysosomal enzymes, so the term fits the paper's wording precisely and nothing more general has to be used. The claim is a direct ultrastructural observation on the gene product itself, hence IDA, and it is not a mechanism paper being read as a localization, since the localisation is its own reported result. It complements rather than replaces the GO:0031410 rows, which describe the separate free-chagasin vesicle pool. The cached source is abstract-only, but the abstract states the localisation result explicitly. Supporting Evidence: PMID:15713748 Ultrastructural studies showed that chagasin and cruzipain both localize to the Golgi complex and reservosomes (lysosome-like organelles), whereas free chagasin was found in small intracellular vesicles |
| GO:0005794 Golgi apparatus | IDA PMID:15713748 Chagasin, the endogenous cysteine-protease inhibitor of Tryp... | NEW | Summary: The same ultrastructural study placed chagasin and cruzipain together in the Golgi complex, the point in the secretory pathway where the two trafficking routes first intersect. GOA carries no Golgi row for this gene. Reason: A direct ultrastructural localisation of the gene product, so IDA. Under the root-organelle policy the Golgi term is informative in its own right and is added at the root rather than pushed down to a sub-compartment. The EM identified the organelle but there is no second independent line (no cleavable targeting signal, no sub-organelle assay, no membrane topology, and chagasin has neither a transmembrane segment nor an annotated signal peptide) that would fix it to a cisternal membrane or lumen, so a GO:0000139 Golgi membrane row would overreach. This is kept as a location annotation only and is not advanced as the site of the core activity, since the complexes were recovered from whole epimastigotes rather than from a resolved compartment. Supporting Evidence: PMID:15713748 Ultrastructural studies showed that chagasin and cruzipain both localize to the Golgi complex and reservosomes (lysosome-like organelles), whereas free chagasin was found in small intracellular vesicles PMID:15713748 suggesting that chagasin trafficking pathways might intersect with those of cruzipain |
Loading supporting content…
Download this section (compressed HTML)Q: Does chagasin ever reach a compartment in which it can inhibit a host cathepsin during infection? The structural and kinetic case for inhibition of human cathepsins L and B is strong but entirely in vitro, and the only hint of an extracellular pool is the upregulated secretion of cruzipain-chagasin complexes seen in transfectants. Until this is answered, no symbiont-mediated process term can be justified for this gene, and the distinction between inhibiting the parasite's own cruzipain and inhibiting host proteases remains the single most consequential open question for its annotation.
Q: What is the loss-of-function phenotype? Every genetic result for chagasin is gain-of-function (overexpression transfectants). A null or conditional knockdown would settle whether chagasin is required to keep cruzipain activity within bounds or merely able to suppress it when supplied in excess, which is the difference between a constitutive regulator and a buffer.
Q: Is the regulatory event the formation of complexes inside a compartment, or the intersection of two trafficking itineraries, as the discovery paper proposed? Chagasin and cruzipain were found together in the Golgi complex and reservosomes while free chagasin sits in unidentified small vesicles, so the inhibitory encounter may be confined to a specific waypoint rather than occurring throughout the pathway.
Q: Should GO acquire a term for inhibition of a cysteine-type endopeptidase as a biological process? GO:2000117 negative regulation of cysteine-type endopeptidase activity is obsolete, so a highly selective C1-family inhibitor such as chagasin can only be annotated at the class-agnostic GO:0010951, which loses the information that the regulated enzymes are specifically papain-family cysteine peptidases.
Experiment: Infect mammalian cells with wild-type and chagasin-overexpressing T. cruzi and measure host cathepsin L and B activity in situ with cell-permeable activity-based probes (for example biotinylated or fluorescent DCG-04) on host lysosomal fractions separated from parasite compartments, combined with proximity labelling from a tagged chagasin to identify host proteases it actually contacts. A positive result would license a symbiont-mediated modulation-of-host-protease process term; a negative result would confirm that the host-cathepsin affinity is a cross-reactivity of a broad-spectrum C1 inhibitor and should stay confined to the molecular function.
Hypothesis: Chagasin inhibits host cathepsin L or B in infected host cells, not only as purified enzymes.
Type: activity-based protein profiling and proximity labelling in infection
Experiment: Generate CRISPR-Cas9 chagasin-null and tetracycline-regulated knockdown T. cruzi lines and quantify active cysteine peptidase by active-site titration and activity-based probe labelling across epimastigote, metacyclic trypomastigote and amastigote stages, scoring metacyclogenesis rate and mammalian cell infectivity. This supplies the loss-of-function arm that the entire chagasin literature currently lacks and tests whether the GO:0010951 process annotation reflects a constitutive requirement.
Hypothesis: Chagasin is required, not merely sufficient, to restrain endogenous cruzipain activity.
Type: reverse genetics with activity-based protein profiling
Experiment: Apply correlative light and electron microscopy, or immuno-EM with dual gold labelling, to epimastigotes and trypomastigotes expressing a tagged chagasin, quantifying chagasin-cruzipain co-labelling per compartment (Golgi cisternae, reservosome, flagellar pocket, cytoplasmic vesicles, cell surface) and combining this with compartment-resolved fractionation and SDS-resistant complex assays. This would turn the current list of co-localisation compartments into an ordered itinerary and establish which location should be named as the site of the core activity.
Hypothesis: The inhibitory chagasin-cruzipain complex forms at a defined waypoint in the secretory and endocytic pathway rather than throughout it.
Type: correlative immuno-electron microscopy with subcellular fractionation
Loading supporting content…
Download this section (compressed HTML)Loading supporting content…
Download this section (compressed HTML)